🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
30 Servings
Botanical Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

12 mg NE
✅ Within RDA (0.9× RDA of 14 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 12mg UL 35mg
Chainsaw Gold Proprietary Blend
375 mg

Other Ingredients

Gelatin Rice Flour Magnesium Stearate Silicon Dioxide Titanium Dioxide

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult Male (18-50 Years)

Product Information

📋 Directions for Use

Suggested use: Take one (1) Chainsaw Gold capsule daily.

⚠️ Warnings & Precautions

Caution: Seek advice from a health care practitioner to use if you have high blood pressure, heart or thyroid disease, diabetes, difficulty in urination due to an enlarged prostate, or if you are pregnant, nursing, or taking an MAO inhibitor or any prescription drug.

Reduce or discontinue use if nervousness, tremors, sleeplessness, loss of appetite or nausea occur. Do not exceed recommended serving size. Do not use this product if printed inner seal under cap is missing or broken.

Not intended for use by persons under 18 years of age. Keep out of reach of children Must be 18 years of age to use or buy

🧪 Formulation Notes

Explosive climax Endurance Hardness

Additional Information

Limited edition

Keep product at room temperature (59-86 F). Do not expose to excessive heat or moisture.

USA Made in the USA

Follow us Instagram @VigorLabs Twitter @VigorLabs Facebook @VigorLabs

Product Details

UPC / SKU 7 52830 51472 0
DSLD Entry Date 2025-08-22
Product Type Botanical
Form Capsule
Brand Vigor Labs
DSLD ID 334343
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →